- Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93: 2957-68.
This is a review of the largest studies of somatostatins, subcutaneous octreotide, octreotide long-acting formulation (LAR), and slow releasing (SR) lanreotide, which included biochemical end-point data for lanreotide autogel (ATG), and also studies that directly compared the efficacy of octreotide LAR and lanreotide SR.
It concluded that lanreotide ATG and octreotide LAR are equivalent in the control of symptoms.
- Trainer PJ, Ezzat S, D'Souza GA. A randomised, controlled, multicenter trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 2009; 71: 549-57.
The outcome of this study was that pegvisomant monotherapy and adjunctive therapy are viable options for the treatment of patients with acromegaly who are suboptimally controlled on long-acting octreotide.
- Melmed S, Colao A, Barkan A, et al. Acromegaly Consensus Group Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94: 1509-17.
- Turner HE, Wass JAH. Oxford Handbook of Endocrinology and Diabetes. 2nd edition. Oxford, Oxford University Press, 2009.
- Wass JAH. Acromegaly: A handbook of history, current therapy and future prospects. BioScientific, 2009.
Contributed by Dr Raghava Reddy, consultant endocrinologist, Stafford Hospital and Professor John Wass, professor of endocrinology, Churchill Hospital, University of Oxford.